Seminars in Nephrology
Volume 29, Issue 1 , Pages 85-93, January 2009

Vitamin D Therapy for Chronic Kidney Disease

  • Ishir Bhan, MD

      Affiliations

    • Department of Medicine, Renal Unit, Massachusetts General Hospital, Boston, MA
  • ,
  • Ravi Thadhani, MD, MPH

      Affiliations

    • Department of Medicine, Renal Unit, Massachusetts General Hospital, Boston, MA
    • Center for D-Receptor Activation Research (CeDAR) at the Massachusetts General Hospital, Boston, MA
    • Corresponding Author InformationAddress reprint requests to Ravi Thadhani, MD, MPH, Bulfinch 127, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Summary 

Vitamin D has played a central role in the nephrologist's armamentarium, with active vitamin D analogues enjoying broad use for treatment of secondary hyperparathyroidism. Increasing data are now coming to light about the broader biological actions of vitamin D, including wide-ranging effects in several endocrine pathways, cardiovascular disease, infectious disease, and even the progression of chronic kidney disease (CKD). As additional agents are emerging to help with control of metabolic bone disease, these nontraditional pathways of vitamin D action will become increasingly important to consider when formulating a treatment plan. Although the only approved use for vitamin D analogues in CKD is the treatment of secondary hyperparathyroidism, well-conducted clinical trials may soon broaden the scope of this therapy. This article reviews the role of vitamin D therapy in CKD and looks to the answers that future research may bring.

Keywords: Chronic kidney disease, vitamin D, hyperparathyroidism, survival, hemodialysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 R. Thadhani has received grant support from Abbott Laboratories, and speaking honoraria from Abbott Laboratories and Genzyme.

PII: S0270-9295(08)00174-5

doi:10.1016/j.semnephrol.2008.10.010

Seminars in Nephrology
Volume 29, Issue 1 , Pages 85-93, January 2009